.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XX73_Sotorasib.Sotorasib

Information

name:Sotorasib
ATC code:L01XX73
route:oral
n-compartments1

Sotorasib is an orally administered, small-molecule irreversible inhibitor of KRAS G12C, used for the treatment of non-small cell lung cancer (NSCLC) in patients with KRAS G12C mutation. It was approved by the FDA in 2021 and is actively in use for its labeled indication.

Pharmacokinetics

Pharmacokinetic parameters as reported in adult patients with advanced solid tumors, primarily non-small cell lung cancer, after oral administration.

References

    Revisions

    Generated at 2025-07-21T18:21:10Z by OpenModelicaOpenModelica 1.25.1 using GenerateDoc.mos